Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis, Multidrug-Resistant | 42 | 2024 | 935 | 7.530 |
Why?
|
Antitubercular Agents | 38 | 2024 | 1375 | 4.820 |
Why?
|
Tuberculosis | 23 | 2023 | 2016 | 4.380 |
Why?
|
Mycobacterium tuberculosis | 30 | 2024 | 1913 | 4.330 |
Why?
|
Peru | 41 | 2024 | 891 | 3.720 |
Why?
|
HIV Infections | 39 | 2024 | 17346 | 2.600 |
Why?
|
Sputum | 13 | 2024 | 506 | 2.550 |
Why?
|
Cholera | 16 | 2023 | 747 | 2.390 |
Why?
|
Cholera Vaccines | 11 | 2023 | 262 | 2.370 |
Why?
|
Tuberculosis, Pulmonary | 11 | 2024 | 832 | 2.350 |
Why?
|
Nitroimidazoles | 7 | 2024 | 117 | 2.160 |
Why?
|
Oxazoles | 7 | 2024 | 199 | 1.840 |
Why?
|
Rifampin | 10 | 2024 | 339 | 1.650 |
Why?
|
DNA, Bacterial | 5 | 2024 | 1481 | 1.520 |
Why?
|
Rural Population | 24 | 2021 | 2283 | 1.320 |
Why?
|
Anti-HIV Agents | 10 | 2023 | 4524 | 1.250 |
Why?
|
Anti-Retroviral Agents | 8 | 2019 | 1782 | 1.240 |
Why?
|
Antiretroviral Therapy, Highly Active | 11 | 2020 | 1896 | 1.230 |
Why?
|
Mouth Mucosa | 2 | 2020 | 431 | 1.190 |
Why?
|
Medication Adherence | 11 | 2022 | 2176 | 1.120 |
Why?
|
Viral Load | 10 | 2023 | 3330 | 1.050 |
Why?
|
CD4 Lymphocyte Count | 10 | 2020 | 2569 | 1.020 |
Why?
|
Social Support | 10 | 2022 | 2172 | 0.960 |
Why?
|
Haiti | 18 | 2023 | 550 | 0.940 |
Why?
|
Rwanda | 15 | 2020 | 665 | 0.920 |
Why?
|
Food Supply | 6 | 2023 | 544 | 0.900 |
Why?
|
HIV | 6 | 2024 | 1582 | 0.840 |
Why?
|
Reagent Kits, Diagnostic | 2 | 2019 | 239 | 0.730 |
Why?
|
Vaccination | 8 | 2023 | 3381 | 0.700 |
Why?
|
Antibiotics, Antitubercular | 2 | 2019 | 99 | 0.680 |
Why?
|
Clofazimine | 3 | 2024 | 41 | 0.660 |
Why?
|
Adolescent | 41 | 2024 | 88305 | 0.650 |
Why?
|
HIV Long-Term Survivors | 1 | 2019 | 121 | 0.650 |
Why?
|
Gastric Juice | 1 | 2018 | 59 | 0.640 |
Why?
|
Self Disclosure | 1 | 2019 | 249 | 0.620 |
Why?
|
Feces | 3 | 2019 | 1495 | 0.590 |
Why?
|
Suction | 1 | 2018 | 265 | 0.580 |
Why?
|
Psychometrics | 3 | 2017 | 3064 | 0.570 |
Why?
|
Humans | 137 | 2024 | 761326 | 0.560 |
Why?
|
Urban Population | 3 | 2017 | 2033 | 0.560 |
Why?
|
Infectious Disease Transmission, Vertical | 3 | 2014 | 1351 | 0.560 |
Why?
|
Drug Resistance, Bacterial | 3 | 2019 | 1058 | 0.560 |
Why?
|
Pyrazinamide | 2 | 2024 | 60 | 0.550 |
Why?
|
Mouth | 1 | 2019 | 380 | 0.540 |
Why?
|
Diagnostic Tests, Routine | 2 | 2021 | 787 | 0.540 |
Why?
|
Patient Compliance | 5 | 2022 | 2690 | 0.540 |
Why?
|
Adult | 68 | 2024 | 221122 | 0.530 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2020 | 611 | 0.510 |
Why?
|
Social Stigma | 3 | 2023 | 769 | 0.510 |
Why?
|
Health Literacy | 1 | 2020 | 444 | 0.490 |
Why?
|
Treatment Outcome | 33 | 2024 | 64645 | 0.480 |
Why?
|
Child | 31 | 2024 | 80156 | 0.480 |
Why?
|
Delivery of Health Care, Integrated | 3 | 2019 | 942 | 0.470 |
Why?
|
Female | 84 | 2024 | 392485 | 0.470 |
Why?
|
Entamoebiasis | 1 | 2013 | 12 | 0.460 |
Why?
|
Protozoan Infections | 1 | 2013 | 38 | 0.460 |
Why?
|
Amebiasis | 1 | 2013 | 33 | 0.460 |
Why?
|
Giardiasis | 1 | 2013 | 28 | 0.460 |
Why?
|
Blastocystis Infections | 1 | 2013 | 17 | 0.450 |
Why?
|
Breast Feeding | 2 | 2021 | 1358 | 0.450 |
Why?
|
Male | 78 | 2024 | 360621 | 0.450 |
Why?
|
Young Adult | 34 | 2024 | 59196 | 0.430 |
Why?
|
Mental Health Services | 3 | 2020 | 1730 | 0.420 |
Why?
|
Depressive Disorder | 2 | 2017 | 3728 | 0.420 |
Why?
|
Child, Preschool | 20 | 2022 | 42251 | 0.400 |
Why?
|
Fluoroquinolones | 4 | 2022 | 308 | 0.390 |
Why?
|
Administration, Oral | 9 | 2024 | 4013 | 0.380 |
Why?
|
Vulnerable Populations | 1 | 2017 | 702 | 0.380 |
Why?
|
Sexual Behavior | 2 | 2021 | 2179 | 0.360 |
Why?
|
Infant | 20 | 2021 | 36202 | 0.360 |
Why?
|
Parasitemia | 2 | 2010 | 165 | 0.350 |
Why?
|
Sexual Partners | 1 | 2014 | 796 | 0.330 |
Why?
|
Family Characteristics | 6 | 2019 | 1003 | 0.330 |
Why?
|
Vaccines, Inactivated | 4 | 2019 | 179 | 0.330 |
Why?
|
Directly Observed Therapy | 3 | 2018 | 139 | 0.330 |
Why?
|
Case-Control Studies | 12 | 2024 | 22124 | 0.330 |
Why?
|
Diarrhea | 4 | 2023 | 1319 | 0.320 |
Why?
|
Vibrio cholerae O1 | 3 | 2023 | 243 | 0.320 |
Why?
|
Drug Resistance, Multiple, Bacterial | 5 | 2018 | 589 | 0.310 |
Why?
|
Condoms | 2 | 2021 | 331 | 0.310 |
Why?
|
Infant, Newborn | 14 | 2024 | 26211 | 0.310 |
Why?
|
Malnutrition | 2 | 2016 | 644 | 0.310 |
Why?
|
Prospective Studies | 20 | 2024 | 54405 | 0.300 |
Why?
|
Health Behavior | 1 | 2019 | 2641 | 0.300 |
Why?
|
Cohort Studies | 19 | 2022 | 41440 | 0.300 |
Why?
|
Feeding Behavior | 2 | 2017 | 3187 | 0.300 |
Why?
|
Middle Aged | 37 | 2024 | 220774 | 0.290 |
Why?
|
Sensitivity and Specificity | 8 | 2023 | 14665 | 0.290 |
Why?
|
Bacterial Proteins | 1 | 2021 | 3847 | 0.290 |
Why?
|
Communicable Disease Control | 2 | 2011 | 849 | 0.290 |
Why?
|
Verbal Behavior | 1 | 2008 | 335 | 0.280 |
Why?
|
Reproducibility of Results | 7 | 2024 | 20092 | 0.280 |
Why?
|
Substance-Related Disorders | 3 | 2019 | 4419 | 0.280 |
Why?
|
Mass Screening | 3 | 2024 | 5428 | 0.280 |
Why?
|
Specimen Handling | 3 | 2022 | 703 | 0.280 |
Why?
|
Stereotyping | 1 | 2008 | 239 | 0.270 |
Why?
|
Health Status Indicators | 1 | 2012 | 968 | 0.270 |
Why?
|
Language | 3 | 2023 | 1539 | 0.250 |
Why?
|
Treatment Refusal | 1 | 2008 | 429 | 0.240 |
Why?
|
Drug Repositioning | 2 | 2024 | 233 | 0.240 |
Why?
|
Qualitative Research | 3 | 2022 | 3025 | 0.230 |
Why?
|
Research Design | 2 | 2019 | 6178 | 0.230 |
Why?
|
Lesotho | 1 | 2024 | 74 | 0.230 |
Why?
|
Quality of Life | 3 | 2014 | 13355 | 0.220 |
Why?
|
Malaria | 2 | 2010 | 1227 | 0.210 |
Why?
|
Vibrio cholerae | 3 | 2021 | 793 | 0.210 |
Why?
|
Algorithms | 2 | 2023 | 14025 | 0.210 |
Why?
|
Clinical Protocols | 4 | 2024 | 1440 | 0.210 |
Why?
|
Retrospective Studies | 27 | 2023 | 80575 | 0.210 |
Why?
|
Depression | 5 | 2024 | 8122 | 0.210 |
Why?
|
Diet | 3 | 2017 | 8074 | 0.210 |
Why?
|
Self Report | 5 | 2023 | 3724 | 0.210 |
Why?
|
Regression Analysis | 4 | 2019 | 6341 | 0.200 |
Why?
|
Survival Analysis | 3 | 2014 | 10075 | 0.200 |
Why?
|
Caregivers | 3 | 2020 | 2235 | 0.200 |
Why?
|
Health Personnel | 2 | 2022 | 3335 | 0.200 |
Why?
|
Microbial Sensitivity Tests | 7 | 2018 | 1956 | 0.200 |
Why?
|
Urinalysis | 1 | 2024 | 368 | 0.200 |
Why?
|
HIV-1 | 3 | 2018 | 6860 | 0.190 |
Why?
|
Interpersonal Relations | 2 | 2019 | 1436 | 0.190 |
Why?
|
Tuberculin Test | 2 | 2019 | 206 | 0.180 |
Why?
|
Health Promotion | 1 | 2013 | 2213 | 0.180 |
Why?
|
Community Health Services | 2 | 2018 | 656 | 0.180 |
Why?
|
Selection Bias | 1 | 2022 | 359 | 0.180 |
Why?
|
Factor Analysis, Statistical | 1 | 2023 | 999 | 0.180 |
Why?
|
Pilot Projects | 4 | 2024 | 8632 | 0.180 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 3 | 2010 | 85 | 0.180 |
Why?
|
Feasibility Studies | 3 | 2021 | 5247 | 0.180 |
Why?
|
Body Mass Index | 4 | 2024 | 12949 | 0.180 |
Why?
|
Focus Groups | 2 | 2024 | 1414 | 0.180 |
Why?
|
Home Childbirth | 1 | 2020 | 55 | 0.170 |
Why?
|
Mental Health | 4 | 2024 | 3248 | 0.170 |
Why?
|
Hepatitis C | 2 | 2020 | 1584 | 0.170 |
Why?
|
Cross-Sectional Studies | 8 | 2023 | 26108 | 0.170 |
Why?
|
Socioeconomic Factors | 8 | 2020 | 7824 | 0.170 |
Why?
|
Aged | 16 | 2024 | 169179 | 0.160 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2011 | 2152 | 0.160 |
Why?
|
Pregnancy | 7 | 2024 | 29858 | 0.160 |
Why?
|
Predictive Value of Tests | 3 | 2024 | 15262 | 0.160 |
Why?
|
Mexico | 2 | 2020 | 763 | 0.150 |
Why?
|
Follow-Up Studies | 6 | 2024 | 39108 | 0.150 |
Why?
|
Aged, 80 and over | 7 | 2021 | 58946 | 0.150 |
Why?
|
Antibodies, Bacterial | 4 | 2019 | 1469 | 0.150 |
Why?
|
Primary Health Care | 3 | 2020 | 4685 | 0.150 |
Why?
|
Receptors, Interleukin-12 | 1 | 2017 | 26 | 0.150 |
Why?
|
Blood Donors | 1 | 2020 | 345 | 0.150 |
Why?
|
Self-Help Groups | 1 | 2019 | 192 | 0.150 |
Why?
|
Vitamin E Deficiency | 1 | 2018 | 30 | 0.150 |
Why?
|
Developing Countries | 4 | 2022 | 2887 | 0.150 |
Why?
|
Self Efficacy | 1 | 2022 | 637 | 0.150 |
Why?
|
Papua New Guinea | 2 | 2014 | 46 | 0.150 |
Why?
|
Sex Distribution | 2 | 2014 | 2281 | 0.150 |
Why?
|
Geologic Sediments | 1 | 2018 | 80 | 0.150 |
Why?
|
O Antigens | 1 | 2019 | 196 | 0.140 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 1722 | 0.140 |
Why?
|
Urban Health | 1 | 2020 | 533 | 0.140 |
Why?
|
Vitamin A Deficiency | 1 | 2017 | 88 | 0.140 |
Why?
|
Molecular Typing | 1 | 2017 | 116 | 0.140 |
Why?
|
STAT Transcription Factors | 1 | 2017 | 188 | 0.140 |
Why?
|
Seroepidemiologic Studies | 3 | 2023 | 397 | 0.140 |
Why?
|
Delayed Diagnosis | 1 | 2020 | 462 | 0.140 |
Why?
|
Chromatography, Affinity | 1 | 2017 | 532 | 0.140 |
Why?
|
Prevalence | 9 | 2022 | 15719 | 0.130 |
Why?
|
Logistic Models | 6 | 2019 | 13251 | 0.130 |
Why?
|
Receptors, Interleukin-6 | 1 | 2017 | 225 | 0.130 |
Why?
|
Rural Health Services | 1 | 2020 | 384 | 0.130 |
Why?
|
Interviews as Topic | 3 | 2013 | 2696 | 0.130 |
Why?
|
Mass Vaccination | 1 | 2017 | 109 | 0.130 |
Why?
|
Drug Therapy, Combination | 6 | 2024 | 6309 | 0.130 |
Why?
|
Immunization, Secondary | 1 | 2018 | 368 | 0.130 |
Why?
|
Contact Tracing | 3 | 2017 | 271 | 0.130 |
Why?
|
Immunization Programs | 1 | 2018 | 268 | 0.130 |
Why?
|
Risk Factors | 15 | 2020 | 74152 | 0.130 |
Why?
|
Lipopolysaccharides | 2 | 2021 | 2206 | 0.120 |
Why?
|
DNA Gyrase | 1 | 2016 | 85 | 0.120 |
Why?
|
Health Facilities | 1 | 2020 | 580 | 0.120 |
Why?
|
Hepatitis B | 1 | 2020 | 707 | 0.120 |
Why?
|
Breast Neoplasms | 1 | 2022 | 21009 | 0.120 |
Why?
|
Time Factors | 9 | 2020 | 39974 | 0.120 |
Why?
|
Social Environment | 1 | 2019 | 1020 | 0.120 |
Why?
|
Entamoeba | 1 | 2013 | 5 | 0.120 |
Why?
|
Endolimax | 1 | 2013 | 6 | 0.120 |
Why?
|
Blastocystis hominis | 1 | 2013 | 6 | 0.120 |
Why?
|
Residence Characteristics | 2 | 2014 | 2092 | 0.120 |
Why?
|
Giardia lamblia | 1 | 2013 | 23 | 0.110 |
Why?
|
Vibrio cholerae O139 | 1 | 2014 | 54 | 0.110 |
Why?
|
Capacity Building | 1 | 2016 | 258 | 0.110 |
Why?
|
Vitamin E | 1 | 2018 | 871 | 0.110 |
Why?
|
Marital Status | 1 | 2014 | 426 | 0.110 |
Why?
|
Interleukins | 1 | 2017 | 782 | 0.100 |
Why?
|
Survival | 1 | 2013 | 160 | 0.100 |
Why?
|
Case Management | 1 | 2014 | 272 | 0.100 |
Why?
|
Peer Group | 1 | 2018 | 692 | 0.100 |
Why?
|
Electrolytes | 2 | 2022 | 274 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1088 | 0.100 |
Why?
|
Environmental Exposure | 2 | 2019 | 4463 | 0.100 |
Why?
|
Mammography | 1 | 2022 | 2429 | 0.090 |
Why?
|
Cost-Benefit Analysis | 1 | 2024 | 5492 | 0.090 |
Why?
|
Adolescent Behavior | 1 | 2019 | 1186 | 0.090 |
Why?
|
Poverty | 1 | 2022 | 2697 | 0.090 |
Why?
|
Secondary Prevention | 2 | 2016 | 1474 | 0.090 |
Why?
|
Biopsy | 1 | 2022 | 6768 | 0.090 |
Why?
|
Mothers | 1 | 2021 | 2192 | 0.090 |
Why?
|
Empathy | 1 | 2014 | 473 | 0.090 |
Why?
|
Pandemics | 4 | 2023 | 8635 | 0.080 |
Why?
|
Vitamin D Deficiency | 1 | 2019 | 1385 | 0.080 |
Why?
|
Severity of Illness Index | 3 | 2014 | 15835 | 0.080 |
Why?
|
Drug Costs | 1 | 2018 | 1183 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2018 | 3777 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2014 | 4014 | 0.080 |
Why?
|
Population Surveillance | 2 | 2010 | 2603 | 0.080 |
Why?
|
Child Mortality | 1 | 2011 | 205 | 0.080 |
Why?
|
Principal Component Analysis | 1 | 2012 | 943 | 0.080 |
Why?
|
Proportional Hazards Models | 5 | 2014 | 12450 | 0.080 |
Why?
|
Program Evaluation | 1 | 2017 | 2494 | 0.080 |
Why?
|
Age Distribution | 1 | 2014 | 2880 | 0.080 |
Why?
|
Pain Measurement | 1 | 2018 | 3552 | 0.080 |
Why?
|
Data Collection | 1 | 2017 | 3324 | 0.080 |
Why?
|
Premature Birth | 1 | 2020 | 1782 | 0.070 |
Why?
|
Recombinant Proteins | 1 | 2017 | 6525 | 0.070 |
Why?
|
Immunoglobulin A | 3 | 2016 | 980 | 0.070 |
Why?
|
Immunoglobulin G | 4 | 2023 | 4550 | 0.070 |
Why?
|
Nutritional Status | 1 | 2016 | 1613 | 0.070 |
Why?
|
Organizational Objectives | 1 | 2009 | 426 | 0.070 |
Why?
|
Leptin | 1 | 2015 | 1595 | 0.070 |
Why?
|
Family | 1 | 2018 | 3197 | 0.070 |
Why?
|
Body Weight | 1 | 2017 | 4614 | 0.070 |
Why?
|
Health Surveys | 2 | 2019 | 4059 | 0.070 |
Why?
|
Ofloxacin | 2 | 2015 | 66 | 0.070 |
Why?
|
World Health Organization | 2 | 2023 | 1320 | 0.070 |
Why?
|
Emotions | 1 | 2018 | 2738 | 0.060 |
Why?
|
Vitamin D | 1 | 2019 | 3304 | 0.060 |
Why?
|
B-Lymphocytes | 1 | 2019 | 4764 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 4567 | 0.060 |
Why?
|
Education | 1 | 2008 | 536 | 0.060 |
Why?
|
Kazakhstan | 1 | 2024 | 19 | 0.060 |
Why?
|
Ambulatory Care | 2 | 2013 | 2775 | 0.060 |
Why?
|
Age Factors | 2 | 2019 | 18401 | 0.060 |
Why?
|
Moldova | 1 | 2024 | 14 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3204 | 0.060 |
Why?
|
Cycloserine | 1 | 2024 | 118 | 0.060 |
Why?
|
Hospitalization | 3 | 2015 | 10715 | 0.050 |
Why?
|
Antacids | 1 | 2023 | 94 | 0.050 |
Why?
|
Comorbidity | 2 | 2014 | 10498 | 0.050 |
Why?
|
Incidence | 5 | 2020 | 21336 | 0.050 |
Why?
|
Reverse Transcription | 1 | 2022 | 47 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2024 | 4850 | 0.050 |
Why?
|
Epidemics | 2 | 2021 | 511 | 0.050 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2012 | 6019 | 0.050 |
Why?
|
Russia | 2 | 2014 | 384 | 0.050 |
Why?
|
Antibodies, Viral | 2 | 2023 | 3155 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5841 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2011 | 2691 | 0.050 |
Why?
|
Genes, Bacterial | 2 | 2017 | 1079 | 0.050 |
Why?
|
Cost of Illness | 1 | 2010 | 1935 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2013 | 4027 | 0.050 |
Why?
|
Anti-Bacterial Agents | 2 | 2016 | 7439 | 0.050 |
Why?
|
Safe Sex | 1 | 2021 | 144 | 0.040 |
Why?
|
Massachusetts | 2 | 2024 | 8837 | 0.040 |
Why?
|
Immunologic Tests | 1 | 2021 | 103 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12059 | 0.040 |
Why?
|
Live Birth | 1 | 2024 | 511 | 0.040 |
Why?
|
Limit of Detection | 1 | 2021 | 272 | 0.040 |
Why?
|
Sierra Leone | 1 | 2020 | 169 | 0.040 |
Why?
|
Hypertension | 1 | 2020 | 8539 | 0.040 |
Why?
|
Nasopharynx | 1 | 2022 | 400 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2016 | 10203 | 0.040 |
Why?
|
Self Care | 1 | 2024 | 796 | 0.040 |
Why?
|
Agriculture | 1 | 1980 | 191 | 0.040 |
Why?
|
Mental Disorders | 3 | 2020 | 6839 | 0.040 |
Why?
|
Genes, MDR | 1 | 2018 | 36 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2012 | 5291 | 0.040 |
Why?
|
Health Services Accessibility | 2 | 2016 | 5439 | 0.040 |
Why?
|
Sex Factors | 1 | 2012 | 10551 | 0.040 |
Why?
|
Automation, Laboratory | 1 | 2018 | 103 | 0.040 |
Why?
|
Health Services | 1 | 2023 | 752 | 0.040 |
Why?
|
Immunoglobulin M | 1 | 2023 | 1530 | 0.040 |
Why?
|
Saliva | 1 | 2022 | 827 | 0.040 |
Why?
|
Population Dynamics | 1 | 1980 | 307 | 0.040 |
Why?
|
Erythromycin | 1 | 1997 | 117 | 0.040 |
Why?
|
Legionella pneumophila | 1 | 1997 | 49 | 0.040 |
Why?
|
South Africa | 2 | 2013 | 1841 | 0.040 |
Why?
|
Conservation of Natural Resources | 1 | 1980 | 211 | 0.040 |
Why?
|
Demography | 2 | 2019 | 1648 | 0.040 |
Why?
|
Gender Identity | 1 | 2023 | 766 | 0.040 |
Why?
|
Democratic People's Republic of Korea | 1 | 2016 | 12 | 0.030 |
Why?
|
Health Policy | 1 | 2009 | 2684 | 0.030 |
Why?
|
Hepatitis B virus | 1 | 2020 | 529 | 0.030 |
Why?
|
Antibody-Producing Cells | 1 | 2016 | 140 | 0.030 |
Why?
|
Isoniazid | 1 | 2018 | 283 | 0.030 |
Why?
|
Triage | 1 | 2023 | 986 | 0.030 |
Why?
|
Genotype | 3 | 2018 | 12982 | 0.030 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2018 | 330 | 0.030 |
Why?
|
Blood Bactericidal Activity | 1 | 2015 | 126 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2023 | 1334 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2329 | 0.030 |
Why?
|
Poverty Areas | 1 | 2016 | 267 | 0.030 |
Why?
|
Mentors | 1 | 2020 | 660 | 0.030 |
Why?
|
Signal Transduction | 1 | 2017 | 23427 | 0.030 |
Why?
|
Vitamin A | 1 | 2017 | 613 | 0.030 |
Why?
|
Carotenoids | 1 | 2017 | 621 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1703 | 0.030 |
Why?
|
Appointments and Schedules | 1 | 2018 | 443 | 0.030 |
Why?
|
Bacterial Load | 1 | 2014 | 151 | 0.030 |
Why?
|
Microbial Viability | 1 | 2015 | 238 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2021 | 2193 | 0.030 |
Why?
|
Employment | 1 | 1980 | 1118 | 0.030 |
Why?
|
Hepacivirus | 1 | 2020 | 1337 | 0.030 |
Why?
|
Delivery, Obstetric | 1 | 2020 | 940 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2016 | 590 | 0.030 |
Why?
|
Bangladesh | 1 | 2015 | 731 | 0.030 |
Why?
|
Ciprofloxacin | 1 | 2015 | 312 | 0.030 |
Why?
|
Cholera Toxin | 1 | 2015 | 559 | 0.030 |
Why?
|
Health Status Disparities | 1 | 2024 | 1852 | 0.030 |
Why?
|
Recurrence | 3 | 2016 | 8470 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14597 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2024 | 3577 | 0.020 |
Why?
|
Immunologic Memory | 1 | 2019 | 1359 | 0.020 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2018 | 803 | 0.020 |
Why?
|
Protein-Energy Malnutrition | 1 | 2012 | 189 | 0.020 |
Why?
|
Endemic Diseases | 1 | 2012 | 190 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2012 | 573 | 0.020 |
Why?
|
Mutation | 1 | 2016 | 30044 | 0.020 |
Why?
|
Drug Therapy | 1 | 2014 | 503 | 0.020 |
Why?
|
Disease Progression | 2 | 2018 | 13500 | 0.020 |
Why?
|
Pentamidine | 1 | 1990 | 44 | 0.020 |
Why?
|
Anti-Infective Agents | 1 | 1997 | 984 | 0.020 |
Why?
|
Public Health | 1 | 2023 | 2667 | 0.020 |
Why?
|
Treatment Failure | 1 | 2016 | 2642 | 0.020 |
Why?
|
Patient Dropouts | 1 | 2012 | 412 | 0.020 |
Why?
|
United Nations | 1 | 2009 | 150 | 0.020 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2012 | 662 | 0.020 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1990 | 242 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3357 | 0.020 |
Why?
|
Monocytes | 1 | 1997 | 2573 | 0.020 |
Why?
|
Protective Devices | 1 | 2008 | 72 | 0.020 |
Why?
|
Phylogeny | 1 | 2016 | 2809 | 0.020 |
Why?
|
Mosquito Control | 1 | 2008 | 106 | 0.020 |
Why?
|
HIV Seronegativity | 1 | 2008 | 211 | 0.020 |
Why?
|
Income | 1 | 2016 | 1876 | 0.020 |
Why?
|
Odds Ratio | 1 | 2019 | 9639 | 0.020 |
Why?
|
Protein Binding | 1 | 2017 | 9351 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2016 | 4740 | 0.010 |
Why?
|
Quality Improvement | 1 | 2020 | 3800 | 0.010 |
Why?
|
Diffusion of Innovation | 1 | 2009 | 727 | 0.010 |
Why?
|
HIV Seropositivity | 1 | 1990 | 960 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2013 | 6231 | 0.010 |
Why?
|
Blood Pressure | 1 | 2020 | 8485 | 0.010 |
Why?
|
Risk | 1 | 2016 | 9605 | 0.010 |
Why?
|
United States | 2 | 2023 | 72317 | 0.010 |
Why?
|
Cell Line | 1 | 2017 | 15599 | 0.010 |
Why?
|
RNA, Viral | 1 | 2012 | 2846 | 0.010 |
Why?
|
Infection Control | 1 | 2010 | 985 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10764 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5334 | 0.010 |
Why?
|
Antimalarials | 1 | 2008 | 907 | 0.010 |
Why?
|
Respiratory Insufficiency | 1 | 2010 | 1230 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1990 | 2199 | 0.010 |
Why?
|
Population Characteristics | 1 | 1980 | 13 | 0.010 |
Why?
|
Africa, Western | 1 | 1980 | 159 | 0.010 |
Why?
|
Population | 1 | 1980 | 141 | 0.010 |
Why?
|
Economics | 1 | 1980 | 141 | 0.010 |
Why?
|
Radiography | 1 | 2010 | 6966 | 0.010 |
Why?
|
Anemia | 1 | 2008 | 1508 | 0.010 |
Why?
|
Ghana | 1 | 1980 | 315 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 23981 | 0.010 |
Why?
|
Opsonin Proteins | 1 | 1997 | 147 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2015 | 10191 | 0.010 |
Why?
|
Africa | 1 | 1980 | 710 | 0.010 |
Why?
|
Africa South of the Sahara | 1 | 1980 | 743 | 0.010 |
Why?
|
Emigration and Immigration | 1 | 1980 | 396 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8526 | 0.010 |
Why?
|
Environment | 1 | 1980 | 1122 | 0.010 |
Why?
|
Prognosis | 1 | 2012 | 29588 | 0.010 |
Why?
|
Lung | 1 | 2010 | 9994 | 0.010 |
Why?
|
Social Class | 1 | 1980 | 2005 | 0.010 |
Why?
|
Mice | 1 | 2017 | 81474 | 0.010 |
Why?
|
Zidovudine | 1 | 1990 | 624 | 0.000 |
Why?
|
Administration, Inhalation | 1 | 1990 | 1156 | 0.000 |
Why?
|
Animals | 1 | 2017 | 168388 | 0.000 |
Why?
|